HspX protein as a candidate vaccine against Mycobacterium tuberculosis: an overview
- 5 Downloads
Tuberculosis (TB) is a contagious infectious disease caused by Mycobacterium tuberculosis (Mtb). This disease with two million deaths per year has the highest mortality rate among bacterial infections. The only available vaccine against TB is BCG vaccine. BCG is an effective vaccine against TB in childhood, however, due to some limitations, has not proper efficiency in adults. Also, BCG cannot produce an adequately protective response against reactivation of latent infections.
In the present study we will review the most recent findings about contribution of HspX protein in the vaccines against tuberculosis.
Therefore, many attempts have been made to improve BCG or to find its replacement. Most of the subunit vaccines for TB in various phases of clinical trials were constructed as prophylactic vaccines using Mtb proteins expressed in the replicating stage. These vaccines might prevent active TB but not reactivation of latent tuberculosis infection (LTBI). A literature search was performed on various online databases (PubMed, Scopus, and Google Scholar) regarding the roles of HspX protein in tuberculosis vaccines.
Ideal subunit post-exposure vaccines should target all forms of TB infection, including active symptomatic and dormant (latent) asymptomatic forms. Among these subunit vaccines, HspX is the most important latent phase antigen of M. tuberculosis with a strong immunological response. There are many studies that have evaluated the immunogenicity of this protein to improve TB vaccine.
According to the studies, HspX protein is a good candidate for development of subunit vaccines against TB infection.
KeywordsHspX protein Mycobacterium tuberculosis vaccine
Unable to display preview. Download preview PDF.
The authors are grateful to our colleagues in Mashhad University of Medical Sciences for their sincerely cooperation.
- Chen L, Xu M, Wang Z Y, Chen B W, Du W X, Su C, Shen X B, Zhao A H, Dong N, Wang Y J, Wang G Z (2010). The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants. FEMS Immunol Med Microbiol, 59(1): 42–52CrossRefPubMedGoogle Scholar
- da Costa A C, Costa-Júnior A O, de Oliveira F M, Nogueira S V, Rosa J D, Resende D P, Kipnis A, Junqueira-Kipnis A P (2014). A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis. PLoS One, 9(11): e112848CrossRefPubMedPubMedCentralGoogle Scholar
- de Sousa E M, da Costa A C, Trentini M M, de AraújoFilho J A, Kipnis A, Junqueira-Kipnis A P (2012). Immunogenicity of a fusion protein containing immunodominant epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in mice and active TBinfection. PLoS One, 7(10): e47781CrossRefPubMedPubMedCentralGoogle Scholar
- Geluk A, Lin M Y, van Meijgaarden K E, Leyten E M, Franken K L, Ottenhoff T H, Klein M R (2007). T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun, 75(6): 2914–2921CrossRefPubMedPubMedCentralGoogle Scholar
- Jung I D, Shin S J, Lee MG, Kang T H, Han H D, Lee S J, Kim WS, Kim H M, Park WS, Kim H W, Yun C H, Lee E K, Wu T C, Park Y M (2014). Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X. J Immunol, 193(3): 1233–1245CrossRefPubMedPubMedCentralGoogle Scholar
- Liang J, Teng X, Yuan X, Zhang Y, Shi C, Yue T, Zhou L, Li J, Fan X (2015). Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis. MolImmunol, 66(2): 392–401Google Scholar
- Lin M Y, Geluk A, Smith S G, Stewart A L, Friggen A H, Franken K L, Verduyn MJ, van Meijgaarden K E, Voskuil MI, Dockrell H M, Huygen K, Ottenhoff T H, Klein M R (2007). Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. I nfect Immun, 75(7): 3523–3530CrossRefGoogle Scholar
- Mosavat A, Soleimanpour S, Farsiani H, Sadeghian H, Ghazvini K, Sankian M, Jamehdar S A, Rezaee S A (2016). Fused Mycobacterium tuberculosis multi-stage immunogens with an Fcdelivery system as a promising approach for the development of a tuberculosis vaccine. Infect Genet Evol, 39: 163–172CrossRefPubMedGoogle Scholar
- Soleimanpour S, Farsiani H, Mosavat A, Ghazvini K, Eydgahi M R, Sankian M, Sadeghian H, Meshkat Z, Rezaee S A (2015). APC targeting enhances immunogenicity of a novel multistage Fc-fusion tuberculosis vaccine in mice. ApplMicrobiol Biotechnol, 99(24): 10467–10480Google Scholar
- Wang X, Zhang J, Liang J, Zhang Y, Teng X, Yuan X, Fan X (2015). Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ + IL-2 + CD4 + and IFN-γ + CD8 + T cells. PLoS One, 10(3): e0122560CrossRefPubMedPubMedCentralGoogle Scholar
- Xin Q, Niu H, Li Z, Zhang G, Hu L, Wang B, Li J, Yu H, Liu W, Wang Y, Da Z, Li R, Xian Q, Wang Y, Zhang Y, Jing T, Ma X, Zhu B (2013). Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PLoS One, 8(8): e72745CrossRefPubMedPubMedCentralGoogle Scholar
- Yuan X, Teng X, Jing Y, Ma J, Tian M, Yu Q, Zhou L, Wang R, Wang W, Li L, Fan X (2015). A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection. Appl Microbiol Biotechnol, 99(24): 10587–10595CrossRefPubMedGoogle Scholar